| Theme | The Present State of Management of Acute Cholangitis and Cholecystitis | |
|---|---|---|
| Title | Antimicrobial Therapy for Acute Cholangitis and Cholecystitis | |
| Publish Date | 2015/09 | |
| Author | Manabu Watanabe | Department of Surgery, Toho University Ohashi Medical Center |
| Author | Hiroshi Matsukiyo | Department of Surgery, Toho University Ohashi Medical Center |
| Author | Shinya Kusachi | Department of Surgery, Toho University Ohashi Medical Center |
| [ Summary ] | Recently, antimicrobial‒resistant strains of intestinal bacterium, such as Escherichia coli and Klebsiella pnemonieae, have been increasingly isolated from bile duct biopsy samples collected from patients with acute cholangitis and cholecystitis. The TG13 were recently revised to address the variation in antimicrobial susceptibility and to alter the criteria used for severity assessment. The TG13 recommends antimicrobial therapy selection and administration based on the severity of community‒acquired infections and also refers to healthcare‒associated biliary infections. Antimicrobial agents should be selected based on the condition, primary causative organism, and severity of the disease. Furthermore, antimicrobial therapies for resistant strains of bacterium should be considered. We refer to variation of bacterium strain and clear evidence in support of antimicrobial therapy for acute cholangitis and cholecystitis with TG13. |
|